Received Oct 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 342XP | — |
the majority of the 0.5 milliliters tribble down to his arm; dose just tribble down on his arm; dose just tribble down on his arm; he was getting the Second dose, 2 years later; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of underdose in a 57-year-old male patient who received Herpes zoster (Shingrix) (batch number 342XP, expiry date 28-APR-2027) for prophylaxis. Previously administered products included Shingrix (received first dose in 2023). On 11-SEP-2025, the patient received the 2nd dose of Shingrix. On 11-SEP-2025, an unknown time after receiving Shingrix, the patient experienced underdose (Verbatim: the majority of the 0.5 milliliters tribble down to his arm), exposure via skin contact (Verbatim: dose just tribble down on his arm), inadvertent exposure to vaccine (Verbatim: dose just tribble down on his arm) and drug dose administration interval too long (Verbatim: he was getting the Second dose, 2 years later). The outcome of the underdose, exposure via skin contact, inadvertent exposure to vaccine and drug dose administration interval too long were not applicable. Additional Information: GSK receipt date: 12-SEP-2025, 15-SEP-2025 The pharmacist administered a Shingrix vaccination using a Vanish Point needle, but the needle retracted prematurely, causing the dose to spill down the patient's arm. The patient was receiving their second dose of Shingrix, two years after the first dose, which was already outside the recommended dosing schedule. Due to the premature retraction, it appeared that the majority of the 0.5 milliliters of the vaccine did not enter the patient's body. The healthcare professional questioned whether it would be appropriate to administer another dose, considering that the patient may not have been administered sufficient amount.